Skip to main content
. 2012 Nov 13;12:45. doi: 10.1186/1475-2867-12-45

Figure 8.

Figure 8

Activity of MK-8776 (i.p.) and MK-1775 (p.o.) in LoVo xenograft bearing mice.A, Each compound, alone or in combination, was dosed at 50 mg/kg BID for 2 days per week over 4 weekly cycles and is indicated with arrows at the bottom of the graph. Control and single agent groups received both or one vehicle, respectively, so that all animals were dosed with equal vehicle volume and frequency. Percent TGI was calculated as 100 * ΔT/ΔC if ΔT > 0 where ΔT = final mean volume – initial mean volume of treated group, ΔC = final mean volume – initial mean volume of vehicle control group, and Ti = initial mean volume of treated group. P value was derived by student’s t-test for combination (n=10) versus MK-1775 treated tumors (n=10) on day 26. B, In the same study described in (A), LoVo tumor growth was tracked through study day 56 following the fourth and final treatment cycle on days 22 and 23. C, ES-2 xenograft tumors were treated as in (A) for 3 treatment cycles, and days of drug administration are indicated by arrows at the bottom of the graph. P value was derived by student's t-test for combination (n=10) versus MK-1775 treated tumors (n=10) on day 18.